Kantarjian HM - Search Results

1

Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.

Kantarjian HM, O'Brien S, Shan J, Aribi A, Garcia-Manero G, Jabbour E, Ravandi F, Cortes J, Davisson J, Issa JP. Kantarjian HM, et al. Cancer. 2007 Jan 15;109(2):265-73. doi: 10.1002/cncr.22376. Cancer. 2007. PMID: 17133405 Free article. Clinical Trial.

2

Bone marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia.

Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Talpaz M, et al. Cancer. 1992 Jan 15;69(2):410-2. doi: 10.1002/1097-0142(19920115)69:2<410::aid-cncr2820690222>3.0.co;2-v. Cancer. 1992. PMID: 1370212

3

Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C + daunorubicin: comparison to patients treated without GM-CSF.

Estey E, Thall PF, Kantarjian H, O'Brien S, Koller CA, Beran M, Gutterman J, Deisseroth A, Keating M. Estey E, et al. Blood. 1992 May 1;79(9):2246-55. Blood. 1992. PMID: 1571541 Free article.

4

Evolution of treatment for acute myelogenous leukemia and myelodysplastic syndrome at M.D. Anderson Cancer Center 1985-1991.

Keating MJ, Estey E, Kantarjian H, Plunkett W, O'Brien S, Koller C, Beran M, Freireich EJ. Keating MJ, et al. Leukemia. 1992;6 Suppl 2:78-80. Leukemia. 1992. PMID: 1578950 Review. No abstract available.

5

AML-associated cytogenetic abnormalities (inv (16), del (16), t(8;21)) in patients with myelodysplastic syndromes.

Estey E, Trujillo JM, Cork A, O'Brien S, Beran M, Kantarjian H, Keating M, Freireich EJ, Stass S. Estey E, et al. Hematol Pathol. 1992;6(1):43-8. Hematol Pathol. 1992. PMID: 1601822

6

CI-973, a new platinum derivative with potential antileukemic activity.

O'Brien S, Kantarjian H, Freireich E, Johnston D, Nguyen K, Beran M. O'Brien S, et al. Cancer Res. 1992 Aug 1;52(15):4130-4. Cancer Res. 1992. PMID: 1638526

7

Fludarabine: a new agent with marked cytoreductive activity in untreated chronic lymphocytic leukemia.

Keating MJ, Kantarjian H, O'Brien S, Koller C, Talpaz M, Schachner J, Childs CC, Freireich EJ, McCredie KB. Keating MJ, et al. J Clin Oncol. 1991 Jan;9(1):44-9. doi: 10.1200/JCO.1991.9.1.44. J Clin Oncol. 1991. PMID: 1702145 Clinical Trial.

8

Mitoxantrone and high-dose etoposide for patients with relapsed or refractory acute leukemia.

O'Brien S, Kantarjian H, Estey E, Koller C, Beran M, McCredie K, Keating M. O'Brien S, et al. Cancer. 1991 Aug 15;68(4):691-4. doi: 10.1002/1097-0142(19910815)68:4<691::aid-cncr2820680404>3.0.co;2-z. Cancer. 1991. PMID: 1855168

9

Development of systemic lupus erythematosus after interferon therapy for chronic myelogenous leukemia.

Schilling PJ, Kurzrock R, Kantarjian H, Gutterman JU, Talpaz M. Schilling PJ, et al. Cancer. 1991 Oct 1;68(7):1536-7. doi: 10.1002/1097-0142(19911001)68:7<1536::aid-cncr2820680713>3.0.co;2-b. Cancer. 1991. PMID: 1893353

10

A phase II study alternating alpha-2a-interferon and gamma-interferon therapy in patients with chronic myelogenous leukemia.

Talpaz M, Kurzrock R, Kantarjian H, Rothberg J, Saks S, Evans L, Gutterman JU. Talpaz M, et al. Cancer. 1991 Nov 15;68(10):2125-30. doi: 10.1002/1097-0142(19911115)68:10<2125::aid-cncr2820681006>3.0.co;2-q. Cancer. 1991. PMID: 1913450 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,122 results

Search Page

Filters